Holen Sie sich die Stockscreener-App
148.87
0.79%
1.24
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BDX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$147.63
Offen:
$147.63
24-Stunden-Volumen:
1.79M
Relative Volume:
0.65
Marktkapitalisierung:
$41.03B
Einnahmen:
$21.37B
Nettoeinkommen (Verlust:
$1.41B
KGV:
37.75
EPS:
3.9437
Netto-Cashflow:
$3.07B
1W Leistung:
+1.25%
1M Leistung:
-2.20%
6M Leistung:
-23.26%
1J Leistung:
-13.18%
1-Tages-Spanne:
$146.25
$149.30
1-Wochen-Bereich:
$142.67
$149.30
52-Wochen-Spanne:
$141.82
$213.08
Becton Dickinson Co Stock (BDX) Company Profile
Firmenname
Becton Dickinson Co
Sektor
Telefon
(201) 847-6800
Adresse
ONE BECTON DR, FRANKLIN LAKES
Compare BDX vs ISRG, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
148.90 | 40.68B | 21.37B | 1.41B | 3.07B | 3.9437 |
ISRG
Intuitive Surgical Inc
|
437.61 | 155.16B | 10.58B | 3.00B | 2.83B | 8.2437 |
ALC
Alcon Inc
|
67.72 | 33.06B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.08 | 31.30B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
208.55 | 30.18B | 5.54B | 1.52B | 1.74B | 10.37 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Fortgesetzt | Goldman | Neutral |
| 2026-02-10 | Fortgesetzt | Barclays | Overweight |
| 2026-02-03 | Fortgesetzt | Citigroup | Buy |
| 2025-09-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-02 | Herabstufung | Goldman | Buy → Neutral |
| 2025-05-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-05-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-05-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-05-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-12-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2022-07-11 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-06-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | Fortgesetzt | Raymond James | Mkt Perform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2020-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-06-01 | Fortgesetzt | Goldman | Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-07 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-02-07 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-01-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-05-13 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-12-07 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Equal Weight |
| 2018-06-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-04-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-01-19 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-01-05 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-01-05 | Eingeleitet | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2017-12-29 | Bestätigt | Deutsche Bank | Buy |
Alle ansehen
Becton Dickinson Co Aktie (BDX) Neueste Nachrichten
Microneedle Drug Delivery Systems Market to Hit USD 14.37 Billion by 2035 Driven by Self-Administered Therapies – SNS Insider - GlobeNewswire Inc.
Becton, Dickinson And Company (BDX): Evaluating Growth Potential With A 24% Upside - DirectorsTalk Interviews
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MSN
Elyra Kidney Stone Laser Launch Tests Becton Dickinson Execution Story - simplywall.st
BD Delivers Kidney Stone Care for Urology Teams with the Elyra Thulium Fiber Laser System - Finviz
New BD laser targets smoother, quieter kidney stone care procedures - Stock Titan
Becton Dickinson and Co stock (US0758871091): new €600 million notes and recent loss raise questio - AD HOC NEWS
Becton, Dickinson and Company (BDX) Announces €600 Million Notes Offering - GuruFocus
Becton Dickinson Euro Finance Issues €600 Million 3.855% Notes Due 2033 Guaranteed by BD - Minichart
Becton Dickinson subsidiary issues €600 million in 3.855% notes due 2033 - Investing.com Canada
Becton Dickinson Issues €600 Million 3.855% Notes Due 2033 to Refinance 2026 Debt - TradingView
Deals tracker: Medtronic to acquire SPR Therapeutics for $650M - Modern Healthcare
A Look at Becton Dickinson & Co (BDX) After 3.2% Gain -- GF Value $194.45 vs Price $146.95 - GuruFocus
Nebulizers - GlobeNewswire Inc.
BDX Stock Price, Quote & Chart | BECTON DICKINSON AND CO (NYSE:BDX) - ChartMill
Is Wall Street Bullish or Bearish on Becton, Dickinson and Company Stock? - Barchart.com
BD Names Peter Menziuso to Lead $BD Interventional Business - citybiz
Becton, Dickinson and Company Appoints Peter Menziuso as Executive Vice President and President, Bd Interventional, Effective June 1, 2026 - marketscreener.com
Becton, Dickinson and Company (BDX) Stock Analysis: Unveiling a 27.75% Potential Upside - DirectorsTalk Interviews
Becton Dickinson hikes profit outlook, names CFO - MSN
Becton Dickinson and Co stock (US0758871091): earnings beat and strategic focus keep medtech giant i - AD HOC NEWS
DNB Asset Management AS Has $22.28 Million Position in Becton, Dickinson and Company $BDX - MarketBeat
Northwestern Mutual Wealth Management Co. Increases Stock Position in Becton, Dickinson and Company $BDX - MarketBeat
Becton Dickinson (BDX) Delivers Solid Q2 Performance, Barclays Lifts Target - Insider Monkey
Becton Dickinson & Co(BDX) Stock Options Chain | Quotes & News - Moomoo
Becton Dickinson's (NYSE:BDX) Strong Earnings Are Of Good Quality - Moomoo
Becton Dickinson and Co stock (US0758871091): Drops 2.4% to $143.97 after earnings - AD HOC NEWS
Becton Dickinson & Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Becton, Dickinson and Company (BDX) Announces €600 Million Euro Notes Offering - GuruFocus
Becton Dickinson & Co (BDX) News Flow - Moomoo
Becton Dickinson Announces €600 Million Senior Notes Offering - TipRanks
Becton Dickinson launches €600M euro-note offering to refinance 2026 notes - TradingView
This Becton Dickinson Insider Increased Their Holding In The Last Year - Moomoo
Becton, Dickinson and Company $BDX Shares Bought by First Eagle Investment Management LLC - MarketBeat
Crossmark Global Holdings Inc. Grows Stake in Becton, Dickinson and Company $BDX - MarketBeat
May 11, 2026FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses - Becton Dickinson
Is Becton Dickinson & Co (BDX) a Bargain After 4.2% Drop? GF Val - GuruFocus
Becton Dickinson & Co. stock underperforms Monday when compared to competitors - MarketWatch
BD appoints Vitor Roque as permanent CFO - MedTech Dive
Dental Needle Market Is Going to Boom |• BD (Becton Dickinson and Company) • Terumo Corporation - openPR.com
Barclays Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Maintains Target Price $204 - Moomoo
Jim Cramer on Becton, Dickinson: “The Company Showed Excellent Execution Across the Board” - Insider Monkey
Becton, Dickinson and Company Q2 Earnings Call Highlights - sharewise.com
Becton, Dickinson & Co. Hits Day High with Strong 5.87% Surge - Markets Mojo
4: Statement of changes in beneficial ownership of securities - Becton Dickinson
Becton Dickinson & Co. stock outperforms competitors despite losses on the day - MarketWatch
Becton, Dickinson Building Growth After 'Clean' Fiscal Q2 Beat, RBC Says - Moomoo
RBC Capital Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Maintains Target Price $175 - 富途牛牛
Becton, Dickinson and Company (NYSE:BDX) Q2 2026 Earnings Call Transcript - Insider Monkey
Pregnancy Detection Kits Market Analysis Report 2026 - GlobeNewswire Inc.
Research Alert: CFRA Maintains Hold Rating On Shares Of Becton, Dickinson And Company - Moomoo
Finanzdaten der Becton Dickinson Co-Aktie (BDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.12%
0.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):